- Home
- CCCC vs CRAC Comparison
CCCC vs CRAC Comparison
Compare CCCC & CRAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCCC | CRAC |
|---|---|---|
| Founded | 2015 | 2025 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.1M | 216.6M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | CCCC | CRAC |
|---|---|---|
| Price | $2.96 | $10.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $12.20 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 77.9K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,947,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $1.21 | $9.90 |
| 52 Week High | $3.82 | $10.08 |
Technical Indicators
Market Signals| Indicator | CCCC | CRAC |
|---|---|---|
| Relative Strength Index (RSI) | 53.88 | 66.82 |
| Support Level | $2.34 | $9.97 |
| Resistance Level | $3.20 | N/A |
| Average True Range (ATR) | 0.24 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 63.97 | 100.00 |
Price Performance
Historical ComparisonAbout CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About CRAC Crown Reserve Acquisition Corp. I Class A Ordinary Shares
Crown Reserve Acquisition Corp I is a blank check company.